CELC Celcuity Inc

$CELC I learned my lesson from CORT. When a company is generating $750M off a single drug, buy the F OUT OF IT when it dumps during the wider market or a short term binary event $CORT now up 300% in just a year 😭

$CELC every time i leave a board, profits just disappear, fade, vanquish, poof, gone. Welcome me back Jabronis with loving arms if you want green dildo again. If you 👃 👃 👃 what the 📈 is 🧑‍🍳

$CELC real world experience shows without fail: patients take the most efficacious option available within their safety limit. Not one takes an inferior drug out of better safety or convenience in this setting, and most patients live near treatment centers. Therefore this selling has little to do with "fundamentals". It's about being a massive loser that funds must cut due to mandates. Hopefully a few quarters of sales will change perception on the stock. I believe CELC is a $150 company today.

$CELC Super needless nuisance talk of delayed commercial launch. Fuhgettaboutit ! Bobblehead analysts have undermining Q3 revenue estimates from ~$0, ~3M, ~$9M. What say you fellow longs, what will be the first reported sales #, $0 or something different? Would NOT surprise me if on the last day of the quarter they deliver to distributors over $10M in sales. It would not matter either way as this will be blockbuster product!!! Welcome any substantive thoughts.

$CELC The talk of a delayed product launch seems a bit overdone and misplaced. One analyst raised this as an issue. For an expensive drug like this, a J-code is needed, for insurance to pay. Patients can’t afford to pay out of pocket. The product launch is pretty much timed to coincide with the issuance of the J-code, which can’t be applied for until a drug receives FDA approval. So let’s wait and see how this plays out. There should be a lot of news forthcoming by the end of the month.

$CELC October 19: ESMO clinical trial abstracts released. October 23: Prostate cancer Phase 1b/2 trial results presented. October 24: VIKTORIA-1 Phase 3 updated breast cancer data presented. October 24: VIKTORIA-2 Phase 3 first-line breast cancer trial presentation. November 2026 (expected): Q3 earnings and initial REVTORPYK commercial launch update. Date TBD: FDA acceptance and review timeline for PIK3CA-mutant indication. 2027 and beyond: VIKTORIA-2 Phase 3 results and potential expansion into first-line breast cancer treatment.

$CELC Celcuity announced this morning that four REVTORPYK/gedatolisib presentations have been accepted for ESMO 2026, including a late-breaking rapid oral presentation of additional subgroup analyses from the Phase 3 VIKTORIA-1 PIK3CA-mutant cohort. The abstracts will become public October 19, with presentations at ESMO in Madrid October 23–27. There are actually three areas worth watching:

$CELC a couple things: 1. This is a bad chart, and it's bad because commercials weren't up and running on day 1. 2. I've added more at the low 80s. CMC isn't hard for an IV small molecule, I'm not sure what tripped mgmt up here. This situation can be fixed with a proper launch and strong adoption. We shall see how it does going into EOY.

$CELC This October has not been kind to most of biotech.. Will November be the turnaround? I do believe so 🙏🏼 what do you guys think ?

$CELC it’s simple, look at the chart. Has 50 written all over it. Now if you have a mathematically advantageous system, can endure some temporary pain, you will make bank. 7300 10%+ 🚀 rippers and counting.

$CELC I’m going to hibernate for the winter. I have 3 pending sell orders. When I wake up on April 1st, 2027, I better be rich.

$CELC I’m just going to sit back and shut up. I couldn’t have been more wrong about this stock’s performance. I’m speechless. Still holding and hopeful.

$CELC A new FDA approved major cancer therapy and we are stair stepping back down to $50 zone again. Unbelievable and unforgivable.

$CELC David Gryskas is the financial mastermind behind high-growth companies, helping turn ambitious businesses into billion-dollar acquisition targets. He’s been directly involved in deals and acquisitions worth more than $20 billion.

$CELC Management may just have accomplished the most incompetent introduction to market of a blockbuster drug in the history of pharmaceuticals.

$CELC going back to the 50-55 range. incredible how far off the target this is now. almost too good to be true!

📅 CATALYST REMINDER | $CELC October 19, 23 & 24, 2026 — ESMO Abstracts & Clinical Data ESMO abstracts including VIKTORIA-1 (LBA16) are released October 19. Celcuity presents Phase 1b gedatolisib data in metastatic prostate cancer on October 23 and VIKTORIA-1 breast cancer subgroup analyses on October 24. More details in our hub. #CELC #Biotech #ESMO2026

$CELC constant selling. Price action is frustrating but think we'll see some light at the end of the tunnel with Revtorpyk being commercial.

$CELC From 140 to 67, that's the reaction to a rug that failed a P2. I want to see accountability here. They don't get to keep their jobs for this shit show.

$CELC I think this gets bought soon. 110% institutional . An increase from the dip. It would easily fit a BP oncology profile.